ALKS vs VNDA
ALKS: Alkermes is a neuroscience-focused biopharmaceutical company developing and commercializing therapeutic treatments for complex neurological and psychiatric disorders. VNDA: Vanda Pharmaceuticals is a specialty biopharmaceutical company commercializing psychiatric and neurological therapies while advancing a pipeline focused on pharmacogenetic-driven precision medicine.
Side-by-side fundamentals
| Metric | ALKS | VNDA | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $43.48 | $4.01 | |
| Market cap | $7.3B | $242M | |
| P/E as of 2026-10-21 | 114.42 | n/a | |
| Net margin FY2025, SEC XBRL | +16.4% | -102.0% | ALKS higher |
| Operating margin FY2025, SEC XBRL | +17.2% | -70.0% | ALKS higher |
| ROE FY2025, SEC XBRL | +13.3% | -67.4% | ALKS higher |
| ROA FY2025, SEC XBRL | +9.7% | -45.1% | ALKS higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.83 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | -5.3% | +8.7% | VNDA higher |
| Revenue CAGR (3y) SEC XBRL | +9.9% | -5.3% | ALKS higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.68 | 0.64 | |
| 1-year return as of 2026-10-21 close | +38.3% | -24.2% | ALKS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.